Can-Fite BioPharma obtained US Food and Drug Administration (FDA) Orphan Drug Status for CF102 – a drug for primary liver cancer (hepatocellular carcinoma.) The drug was found to be safe in preclinical and Phase I clinical trials. Orphan Drug Status is granted for drugs being developed for the treatment of diseases that affect a small […]